Juluis Scott

Juluis Scott |Clyto Access

SRMU, India


Expertise: Management Of Solid Tumors Especially In Hepatoblastoma, Pediatric Hematology, Pediatric Oncology

Biography: Dr. Julius Scott carried out his postdoctoral research in the Women’s and Children’s Hospital, Adelaide, Australia. Later he started working as a Professor at Sri Ramachandra Medical University, Porur, Chennai. He has many honors and awards.Presently he is working as Head, Division of Pediatric,Hematology and Oncology services, Sri Ramachandra Medical University, Chennai, India.


Title: Recent advances in the management of hepatoblastomas


Hepatoblastomas(HB) constitutes 1% of  childhood cancers, usually occurs in children aged between 6 months and 3 years, but cases in neonates and adolescents have been reported rarely. Next to neuroblastoma, Wilms Tumor, hepatoblastomas are the third most common intraabdominal malignancy in children. With survival rates increasing from 20% to 80% over the past decades, the treatment of HB has been one of the great success stories in pediatric oncology. 

To describe the dramatic revolutionary improvement in the diagnosis, treatment and outcome of children diagnosed with HB that has occurred in the past four decades. 

Important milestones were the risk stratification of HB that allowed to tailor down therapy for standard risk HB and intensify treatment for high-risk HB. The multi-institutional international cooperative SIOPEL trials, the Children's Oncology Group (COG) , the national study groups from Germany (GPOH) and Japan (JPLT) led the progress of the treatment. The use of one staging system (PRETEXT) and the outcome after incorporating liver transplantation increased the outcome.
Currently the treatment of relapsed HB is challenging. In recurrent refractory alternative strategies and combinations of new agents are currently tested, like irinothecan,  targeted agents like sorafenib which we have seen good results.

Related Conferences :